ImmuCell (NASDAQ:ICCC) Share Price Crosses Above 200-Day Moving Average – Here’s Why

ImmuCell Corporation (NASDAQ:ICCC) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.12 and traded as high as $11.35. ImmuCell shares last traded at $11.24, with a volume of 8,689 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ICCC shares. Weiss Ratings restated a “sell (d-)” rating on shares of ImmuCell in a research note on Thursday, July 2nd. Wall Street Zen upgraded shares of ImmuCell to a “strong-buy” rating in a research note on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

ImmuCell Trading Up 0.5%

The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. The company has a market cap of $100.09 million, a price-to-earnings ratio of -184.30 and a beta of 0.56. The business has a fifty day simple moving average of $10.30 and a 200 day simple moving average of $8.16.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.05 by $0.16. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%. The firm had revenue of $10.36 million during the quarter, compared to analysts’ expectations of $5.40 million.

Insider Activity at ImmuCell

In other news, CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The shares were acquired at an average price of $9.49 per share, for a total transaction of $75,920.00. Following the acquisition, the chief executive officer directly owned 17,785 shares in the company, valued at approximately $168,779.65. The trade was a 81.76% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.70% of the stock is owned by company insiders.

Institutional Trading of ImmuCell

A number of institutional investors have recently bought and sold shares of the company. Militia Capital Management LLC purchased a new position in shares of ImmuCell in the first quarter valued at $114,000. Mesirow Financial Investment Management Inc. boosted its position in shares of ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after buying an additional 24,303 shares in the last quarter. Steadtrust LLC boosted its position in shares of ImmuCell by 79.1% in the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock worth $349,000 after buying an additional 25,070 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in ImmuCell by 3.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 1,749 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after acquiring an additional 2,907 shares in the last quarter. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.